Stuttgart - Delayed Quote EUR

AstraZeneca PLC (ZEG.SG)

122.80

+1.75

+(1.45%)

At close: May 12 at 5:19:03 PM GMT+2

Trump’s Vow to Cut US Drug Prices Drags Pharma Stocks Lower

(Bloomberg) -- President Donald Trump said he plans to order a cut in US prescription drug costs to bring them in line with other countries, spurring a drop in pharmaceutical shares worldwide.Most Read from BloombergA New Central Park Amenity, Tailored to Its East Harlem NeighborsAs Trump Reshapes Housing Policy, Renters Face Rollback of RightsWhat’s Behind the Rise in Serious Injuries on New York City’s Streets?NYC Warns of 17% Drop in Foreign Tourists Due to Trump PoliciesLA Mayor Credits Trum

Bloomberg 17 hours ago

AZN

AZNCF

BERZ
Trump’s Plan to Cut Drug Prices Hits Pfizer, Other Pharma Stocks

Drugmakers' shares fell globally after President Trump said he would sign an executive order to lower the cost of prescription drugs. Shares of Japan's Daiichi Sankyo, which gets about a third of revenue from the U.S., dropped around 8%. Other Japanese drug stocks also fell.

The Wall Street Journal 17 hours ago

AZN

AZNCF

PFE
Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices

(Bloomberg) -- Shares of pharmaceutical companies fell across the world after US President Donald Trump said he planned to order a cut in US prescription drug costs to bring them in line with other countries, prompting concern that profits will take a hit.Most Read from BloombergA New Central Park Amenity, Tailored to Its East Harlem NeighborsAs Trump Reshapes Housing Policy, Renters Face Rollback of RightsWhat’s Behind the Rise in Serious Injuries on New York City’s Streets?Is Trump’s Plan to R

Bloomberg 20 hours ago

C

TAK

TKPHF
AstraZeneca (LSE:AZN) Reports Positive Results From Phase III IMFINZI Trial In Bladder Cancer

AstraZeneca (LSE:AZN) recently released positive results from its POTOMAC Phase III trial involving IMFINZI, reflecting significant advancements in treatment for high-risk non-muscle-invasive bladder cancer. This development coincided with a 5.93% share price increase over the past month. The company's recent announcements, such as the Calquence approval in the EU and positive results from the DESTINY-Breast11 trial, have reinforced its commitment to innovative treatments. While market...

Simply Wall St. 2 days ago

AZN

AZNCF
IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial

WILMINGTON, Del., May 09, 2025--Positive high-level results from the POTOMAC Phase III trial showed one year of treatment with AstraZeneca’s IMFINZI® (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) compared to BCG induction and maintenance therapy alone.

Business Wire 3 days ago

AZN

AZNCF
AstraZeneca (LSE:AZN) Reports Positive Phase 3 Trial Results For Breast Cancer Treatment

AstraZeneca (LSE:AZN) recently experienced positive developments, including the European approval of Calquence for mantle cell lymphoma and promising Phase III trial results for ENHERTU in breast cancer. These advances in oncology could add depth to the company's market performance. Meanwhile, broader market trends showed mixed movements, with the Dow Jones and S&P 500 rising, while Nasdaq slipped slightly. Despite a flat market overall last week due to investor anticipation of the Federal...

Simply Wall St. 5 days ago

AZN

AZNCF
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11

WILMINGTON, Del., May 07, 2025--Positive high-level results from the DESTINY-Breast11 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used in the neoadjuvant setting (before surgery) in patients with h

Business Wire 5 days ago

AZN

AZNCF
AstraZeneca's (LON:AZN) Earnings Offer More Than Meets The Eye

The market seemed underwhelmed by last week's earnings announcement from AstraZeneca PLC ( LON:AZN ) despite the...

Simply Wall St. 6 days ago

AZN

AZNCF
AstraZeneca First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

AstraZeneca ( LON:AZN ) First Quarter 2025 Results Key Financial Results Revenue: US$13.6b (up 7.2% from 1Q 2024). Net...

Simply Wall St. 8 days ago

AZN

AZNCF
AstraZeneca (LSE:AZN) Announces Positive Results From Breztri Trials For Uncontrolled Asthma

AstraZeneca (LSE:AZN) recently announced phase III trial results for Breztri Aerosphere, its triple-combination asthma therapy, marking a milestone in improving care standards for asthma patients. This announcement comes amidst the company's robust Q1 2025 financial performance, which showed significant gains in sales, revenue, and net income. Meanwhile, the broader market rose by 1.8% last week, buoyed by positive macroeconomic indicators such as strong jobs data. AstraZeneca's share price...

Simply Wall St. 10 days ago

AZN

AZNCF
Here's what top C-suites are saying about tariffs

US President Trump's tariff policies have created a challenging environment for business leaders. Here's what some executives are saying about navigating tariffs, including CEOs from Coca-Cola (KO), Starbucks (SBUX), and AstraZeneca (AZN), and top executives at Meta (META), General Motors (GM), and Amazon (AMZN). To watch more expert insights and analysis on the latest market action, check out more Wealth here.

Yahoo Finance Video 10 days ago

AAPL

KO

AMZN
BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma

WILMINGTON, Del., May 02, 2025--Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose triple-combination therapy BREZTRI AEROSPHERE (budesonide/glycopyrronium/formoterol fumarate or BGF (320/28.8/9.6μg)) met all primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in lung function compared with dual-combination inhaled corticosteroid/long-acting beta2-agonist (I

Business Wire 10 days ago

AZN

AZNCF
'Declare victory and move on': Eli Lilly CEO on Trump tariff threat

Eli Lilly CEO says Trump tariff threat has already achieved the goal of repatriating manufacturing in pharma.

Yahoo Finance 11 days ago

PFE

JNJ

RHHBF
3 UK Stocks Estimated To Be 21.1% To 46.6% Below Intrinsic Value

The United Kingdom's stock market has recently faced challenges, with the FTSE 100 closing lower due to weak trade data from China and declining commodity prices affecting major companies. In this environment of uncertainty, investors may be on the lookout for stocks that are undervalued relative to their intrinsic value, as these can present potential opportunities despite broader market fluctuations.

Simply Wall St. 11 days ago

AZN

AZNCF

BPT.L
AstraZeneca Tops Earnings Views And Shares Rise Despite Cancer Miss

AstraZeneca stock rose moderately Tuesday despite a mixed first-quarter report and a setback for its experimental prostate cancer treatment.

Investor's Business Daily 13 days ago

AZN

AZNCF
AstraZeneca (LSE:AZN) Reports Higher Earnings, Dividend Increase, and Clinical Trial Discontinuation

AstraZeneca (LSE:AZN) recently announced its first-quarter earnings for 2025, showcasing strong financial performance with revenue rising to USD 13,588 million, up from the previous year. Despite this, the halt of the CAPItello-280 clinical trial might have dimmed enthusiasm. In the context of last week, AstraZeneca's share price rose 4%, reflecting not only the robust earnings boost but also aligned with the broader market's upward trend. The planned dividend increase further substantiates...

Simply Wall St. 13 days ago

AZN

AZNCF
Pfizer CEO: 'We should not have tariffs' on pharma

Like his Big Pharma peers, Pfizer (PFE) CEO Albert Bourla is waiting for the US government to finalize its decision on whether to place a 25% tariff on pharmaceutical imports. To be sure, he said Tuesday, the government's national security concerns are "legitimate." But, he added, "we should not have tariffs."

Yahoo Finance 13 days ago

PFE

AZN

AZNCF
AstraZeneca CEO: Trump tariffs 'not material long term'

AstraZeneca reported first quarter earnings.

Yahoo Finance 13 days ago

AZN

AZNCF
AstraZeneca's 'number 1 priority' is the US, CEO says

AstraZeneca (AZN) reported mixed first quarter earnings results, missing on revenue estimates but beating on earnings per share (EPS). The company also reaffirmed its 2025 outlook and has highlighted its commitment to US investments amid tariff concerns. AstraZeneca CEO Pascal Soriot joins Morning Brief to discuss the outlook for the company and outlines AstraZeneca's plans to expand manufacturing and R&D operations in the US To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.

Yahoo Finance Video 13 days ago

AZN

AZNCF
EsoBiotec to Present Preclinical Proof-of-Concept Data for Its Off-the-Shelf ENaBL In Vivo Cell Therapy Platform at the 28th Annual Meeting of the American Society of Gene and Cell Therapy

Poster talk will present safety and efficacy data for ENaBL-T, a lentiviral vector for in vivo engineering of BCMA CAR T cells, which supported the first in vivo BCMA CAR-T cell therapy clinical trial for patients with relapse or refractory multiple myeloma Company to deliver two additional poster presentations showcasing the development of novel T cell-specific synthetic promoters and a differentiated T cell targeting complex for safer and more effective in vivo CAR-T cell therapies MONT-SAINT-

GlobeNewswire 13 days ago

AZN

AZNCF

Performance Overview

Return	ZEG.SG	FTSE 100 (^FTSE)
YTD	-2.38%	+5.29%
1-Year	-13.30%	+2.03%
3-Year	+12.81%	+18.96%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AstraZeneca PLC (ZEG.SG)

Trump’s Vow to Cut US Drug Prices Drags Pharma Stocks Lower

Trump’s Plan to Cut Drug Prices Hits Pfizer, Other Pharma Stocks

Pharmaceutical Stocks Tumble on Trump Plan to Cut US Drug Prices

AstraZeneca (LSE:AZN) Reports Positive Results From Phase III IMFINZI Trial In Bladder Cancer

IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial

AstraZeneca (LSE:AZN) Reports Positive Phase 3 Trial Results For Breast Cancer Treatment

ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11

AstraZeneca's (LON:AZN) Earnings Offer More Than Meets The Eye

AstraZeneca First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

AstraZeneca (LSE:AZN) Announces Positive Results From Breztri Trials For Uncontrolled Asthma

Here's what top C-suites are saying about tariffs

BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma

'Declare victory and move on': Eli Lilly CEO on Trump tariff threat

3 UK Stocks Estimated To Be 21.1% To 46.6% Below Intrinsic Value

AstraZeneca Tops Earnings Views And Shares Rise Despite Cancer Miss

AstraZeneca (LSE:AZN) Reports Higher Earnings, Dividend Increase, and Clinical Trial Discontinuation

Pfizer CEO: 'We should not have tariffs' on pharma

AstraZeneca CEO: Trump tariffs 'not material long term'

AstraZeneca's 'number 1 priority' is the US, CEO says

EsoBiotec to Present Preclinical Proof-of-Concept Data for Its Off-the-Shelf ENaBL In Vivo Cell Therapy Platform at the 28th Annual Meeting of the American Society of Gene and Cell Therapy

Performance Overview